Sarepta falls on bigger-than-expected Q4 loss

Sarepta Therapeutics

26/02/2026 13:20

** Shares of muscular dystrophy drug maker Sarepta Therapeutics SRPT.O fall 3.5% to $18.30 premarket

** Co reports Q4 loss of $3.93/shr vs analysts' average loss estimate of $1.31/shr - LSEG data

** Sarepta CEO Douglas Ingram says he will step down by the end of 2026 to focus on family commitments

** "In a fairly shocking and certainly ironic twist of fate, my personal commitment to muscular dystrophy has deepened as two of my members of my immediate family have been diagnosed now with myotonic dystrophy, DM1," says Ingram

** Co's quarterly revenue of $442.9 million beats analysts' average expectation of $391.9 million

** Up to last close, stock down 11.9% YTD

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))